Ergocalciferol

MANHASSET, N.Y.--(BUSINESS WIRE)-- Approximately 352,000 Americans under the age of 20 have type 1 diabetes, and every year 64,000 Americans more are diagnosed. To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells. This press release features multimedia. View the full release here: Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes. (Credit: Feinstein Institutes) The study, which was published today in the Journal of the American Medical Association and led by Benjamin Nwosu, MD, chief of endocrinology and director of the diabetes center at Cohen Children’s and researcher with the Feinstein Institutes, looked at a group of young people, ages 10 to 21, who were recently diagnosed with type 1 diabetes. The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes. The honeymoon phase of type 1 diabetes is a crucial time when treatments can make a difference in the long-term outlook of the disease. This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer. “Type 1 diabetes affects millions of people and treatment options can often be costly,” said Dr. Nwosu, who is the principal author of the paper. “It is exciting to know that vitamin D could protect the beta cells of the pancreas and increase the natural production of good and functional insulin in these patients. This, in turn, prolongs the honeymoon phase of type 1 diabetes and leads to reduced long-term complications of this disease.” When a patient is diagnosed with type 1 diabetes, their pancreas does not make enough insulin, a hormone that moves blood sugar into the cells of the body for energy production. Without insulin, blood sugar cannot get into the cells and instead build up in the bloodstream, which could be damaging to the body and cause the symptoms and complications of diabetes. As part of the 12-month randomized clinical trial, one group took ergocalciferol (a type of vitamin D) as treatment, while the other group took a placebo. Researchers found that taking the vitamin D supplement reduced the proinsulin to C-peptide ratio and delayed the loss of C-peptide more than the placebo did. This means that vitamin D protects the cells that make insulin and ensures that good insulin is made. “Repurposing commonly used supplements such as vitamin D, which is known to be safe and effective for other ailments, presents an opportunity to continue developing other therapies needed to treat type 1 diabetes,” said Charles Schleien, MD, MBA, senior vice president and chair of pediatric services at Northwell Health, and the Philip Lanzkowsky Chair and Professor of Pediatrics at the Zucker School of Medicine at Hofstra/Northwell. “Dr. Nwosu’s research is another step forward to continue our understanding of diabetes and the development of more affordable, yet effective treatment options.” This research builds on Dr. Nwosu’s previous work, which showed that the use of high-dose vitamin D supplementation was safe and effective to improve glucose control and prolong the partial clinical remission phase of type 1 diabetes in children and adolescents. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on businesswire.com: Contacts Julianne Mosher Allen 516-880-4824 jmosherallen@northwell.edu Source: Northwell Health Smart Multimedia Gallery Photo Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes. (Credit: Feinstein Institutes) Logo View this news release and multimedia online at:

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes. As a G-protein coupled receptor, the D2 receptor is involved in the regulation of dopamine neurotransmission, which affects mood, motivation, and reward. Dysfunction of the D2 receptor has been implicated in several psychiatric disorders, including schizophrenia and addiction. Additionally, the D2 receptor is a target for antipsychotic medications, which work by blocking its activity to alleviate symptoms associated with psychosis. Understanding the role of the D2 receptor is essential for developing therapeutic interventions for psychiatric and neurological conditions. The analysis of the target D2 receptor reveals a competitive landscape with multiple companies making progress in the development of drugs. Johnson & Johnson, Mitsubishi Chemical Group Corp., Novartis AG, Sanofi, and Viatris Inc. have shown significant growth and have drugs approved for the target. Schizophrenia, bipolar disorder, and bipolar I disorder are the most common indications for approved drugs. Small molecule drugs are progressing rapidly, with intense competition from biosimilars. The United States, Japan, and China are the leading countries in the development of drugs targeting the D2 receptor, with China showing notable progress. Overall, the target D2 receptor presents opportunities for further research and development in the pharmaceutical industry. How do they work?D2 receptor antagonists are a type of medication that block or inhibit the activity of the D2 receptors in the brain. D2 receptors are a subtype of dopamine receptors, which are involved in various neurological processes. By antagonizing or blocking the D2 receptors, these medications can modulate the effects of dopamine in the brain. From a biomedical perspective, D2 receptor antagonists are commonly used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder. In these disorders, there is an imbalance of dopamine activity in the brain, and D2 receptor antagonists help to reduce the excessive dopamine signaling. By blocking the D2 receptors, these medications can help alleviate symptoms such as hallucinations, delusions, and mood disturbances. It is important to note that D2 receptor antagonists may also have side effects due to their broader effects on dopamine signaling. These can include movement disorders, such as parkinsonism, as well as metabolic changes and hormonal imbalances. Therefore, the use of D2 receptor antagonists requires careful monitoring and consideration of the potential risks and benefits for each individual patient. List of D2 receptor AntagonistsThe currently marketed D2 receptor antagonists include: Samidorphan/olanzapineLumateperone TosylateAripiprazole LauroxilCariprazine hydrochlorideBrexpiprazoleLoxapineDA-9701Lurasidone HydrochlorideAsenapine MaleatePaliperidone PalmitateFor more information, please click on the image below. What are D2 receptor antagonists used for?D2 receptor antagonists are commonly used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder.  For more information, please click on the image below to log in and search. How to obtain the latest development progress of D2 receptor antagonists?In the Synapse database, you can keep abreast of the latest research and development advances of D2 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!